AMSTERDAM, the Netherlands, May 24 /PRNewswire/ -- After introducing its Cancer Biomarkers activities at the AACR in April this year, Primagen Holding BV, a molecular diagnostics company, will exhibit its products in booth #4463 at the American Society of Clinical Oncology (ASCO) meeting being held in Atlanta, Georgia, from June 2-6. The company is expanding its focus into the area of clinical oncology with new Clinical Research Services on its multiple mRNA expression markers and free-circulating mtDNA and mtRNA tests.
In addition to a poster on mRNA expression of stem cell marker CD133 as a potential tool to manage metastatic disease, Primagen will also feature data on other mRNA markers including CD169 and CD146. The company will also highlight the novel extension of its Mitox(TM) products for mitochondrial nucleic acids that explore the clinical relevance of free-circulating plasma mtDNA and mtRNA as surrogate markers for assessing tumor progression or regression.
“Research in conjunction with key medical centers in Europe and the United States over the past 12 months has shown that Primagen’s effort in the area of clinical oncology represents a significant opportunity to improve the assessment of numerous solid tumor cancers,” says Steve Owings, President of Primagen Inc., the company’s North American Affiliate. “We plan to begin commercial service testing to the pharmaceutical industry this summer, followed with test kits that can be employed for clinical research and validation.”
Primagen’s Clinical Service Laboratory is based in Amsterdam, The Netherlands. In addition to the new clinical research services, Primagen also offers in-vitro toxicology assessment for antiviral compounds in the area of HIV/AIDS and Hepatitis.
About Primagen Holding B.V.
Primagen is a privately held company headquartered in Amsterdam, The Netherlands. Primagen designs, develops and commercializes molecular tests that have high, individualized predictive value and improve the quality of life for patients suffering from life-threatening diseases, such as infections, AIDS and cancer. Primagen has two proprietary molecular product lines on the market. The Mitox(TM) products measure mitochondrial DNA and RNA in clinical samples with unmatched accuracy. The Dry Fluid Spot (DFS) Rainbow product brings HIV-1 viral load measurement to resource-poor environments. For additional information about Primagen, visit www.primagen.com.
Primagen Holding B.V.
CONTACT: Contact : Primagen Holding B.V., Jos Rijntjes, +31-20-566-8575,p.j.rijntjes@primagen.com
